Our Microbes, Ourselves

28 06 2012

Trillions of bacteria within, essential for immune function, are ours alone

Gut bacteria's key role in immunity is tuned to the host species, researchers have found, suggesting that the superabundant microbes lining our digestive tract evolved with us—a tantalizing clue in the mysterious recent spike in human autoimmune disorders.

A new study reports that the superabundance of microbial life lining our gastrointestinal tracts has coevolved with us. These internal bacteria, which are essential for a healthy immune system, are ultimately our evolutionary partners. In other words, humans may have coevolved with gut bacteria unique to humans, which are not immunologically functional in other mammals.

This study, the first to demonstrate that microbes are specific to their host species, also sheds light on what is called ' the hygiene hypothesis. ' According to this idea, living in increasingly hyper-hygienic environments might contribute to recent spikes in childhood allergies, as these beneficial host-specific microbes are hindered by the plethora of antibacterial home products and cleaning chemicals.

"For every cell in your body that is you, that contains your specific genetic information, there are approximately nine foreign bacterial cells, primarily in your digestive tract and even on your skin,"said Dennis Kasper, William Ellery Channing Professor of Medicine at Harvard Medical School  and senior author on the paper. "From the viewpoint of cell count, every human being is ninety percent microbial. Now we have found that these bacteria, which we need for optimal health, are species specific. "

This paper appeared in the June 22 issue of Cell.

That 500 to 1,000 microbial species inhabit mammals has long been documented. Researchers have suggested that when it comes to digestion and other metabolic activities, the particular species of bacteria may not be significant provided the bacteria contain specific, helpful genes. In otherwords, a bacterium that breaks down food in the mouse gut can probably do the same in the human.

But the microbes that fortify our immune system have not been studied in this regard. Are they functionally unique, or would any species suffice?

To address this question, Hachung Chung, a postdoctoral researcher in Kasper's lab, studied two groups of mice, both of which had been bred to lack microbial flora. For one group, she introduced microbial species that are natural to mice, and to the second, she introduced human microbes.

For both groups of mice, an equal quantity of microbes, and an equal diversity of species, soon flourished in their digestive tracts.

But despite this apparent similarity, when Chung examined the intestinal tissue, including intestinal lymph nodes, of mice from each of the two groups, she discovered that the mice with humanized microbes had surprisingly low levels of immune cells, levels equivalent to mice who lacked intestinal bacteria all together.

"Despite the abundant and complex community of bacteria that were in the human flora mice, it seemed like the mouse host did not recognize the bacteria, as if the mice were germ-free,"said Chung.

Chung repeated the experiment, only this time populating a third group of mice with microbes common to rats. This new group showed the same immune system deficiency as the humanized mice. "I was very surprised to see that,"Chung said. "Naturally, I would have expected more of a half-way response. "

In a third experiment, Chung infected all the mice with salmonella. Almost from day one, the mice with human flora showed significantly higher levels of salmonella in their system than the mice with normal flora. The immune systems of the mice with human flora were effectively incapable of fending off the pathogenic bacteria.

"This raises serious questions regarding our current overuse of antibiotics, as well as ultra-hygienic environments that many of us live in,"said Kasper, HMS professor of microblogy and immunobiology. "If the bacteria within us are specific to us and necessary for normal immune system function, then it's important to know if we are in fact losing these vital bacteria. Are we losing the bacteria we have coevolved with? If that is the case, then this is yet further evidence supporting the idea that the loss of good bacteria is partly to blame for the increased rates of autoimmunity that we are now seeing. "

This work was funded by the Crohn's and Colitis Foundation of America, the Danish Council for Independent Research | Natural Sciences, the National Institutes of Health (grant F32 AI091104), and by an NIH Directors Pioneer Award (DP1OD000964).

Hms.harvard.edu [en línea]   Boston (USA): hms.harvard.edu, 28 de junio de 2012 [REF. 21 in June of 2012] Available on Internet: http://hms.harvard.edu/content/our-microbes-ourselves



Revision of the who on eHealth.

25 06 2012

WHO has chosen the eHealth as a central theme for your bulletin of may.

 

Publishers, current articles and four other research, a systematic review, field experiences and future prospects. In short, a very complete number that will give us to read for hours on the latest developments in eHealth.

You can download it in pdf format, EPUB (with special Kindle Edition) and DAISY (audiobook for visually impaired people).

One of the most interesting articles is María Beatriz Alkmim et to the. It explains how they managed to improve the care patients from the Brazilian region of Minas Gerais through telemedicine.

Is also good to the article by Phil Seidenberg et to the. that presents a study on the use of mobile phones and SMS for the diagnosis of new cases ofHIV in Zambiareducing the time of reporting of new cases of 44 a 26 days, Another new study ontelemedicine in HIV/AIDSand a proof thatmobile phones save lives.

French S Mair et to the. examine the factors that promote or hinder the implementation of eHealth worldwide services. Also John D Piette et to the. discuss new steps for eHealth with medium or low income countries, also Harsha Thirumurthy and Richard T Lester explain how they can deploy mobile health in areas of limited resources.

The most striking is that we see asthose predictionson the relevance of the mobile phones in the future healththey will take force, so increasingly obvious that applications and mobile devices that are used in the field of telemedicine will have to be considereddispositivos médicosand therefore, approved by the relevant regulatory agencies.

These are just a few examples of all the articles of the bulletin.

Can access for free to all them from who website: http://www.who.int/bulletin/volumes/90/5/es/index.html

 

Bulletin of the World Health Organization WHO; Volume 90, Number 5, May 2012, 321-400 DOI: 10.2471/BLT.12.000512 - http://www.somosmedicina.com/2012/05/revision-de-la-oms-sobre-esalud.html

Managementensalud.blogspot.com.es [en línea] Buenos Aires (ARG): managementensalud.blogspot.com.es, 25 de junio de 2012 [REF. 16 in June of 2012] Available on Internet: http://managementensalud.blogspot.com.es/2012/06/revision-de-la-oms-sobre-esalud.html



The 64 per cent of the population do not know the possibility of making a living will

21 06 2012

The 64 per cent of the population do not know the possibility of making a living will. And is that, Although the 84,5 per cent considered it useful and only to the 10 per cent think and speak of death bothers you, only a 6 per cent receive this information by medical personnel, a 22,3 per cent through the media and a 7,5 per cent by friends and family, According to a study carried out in Catalonia and presented at the thirty-second Congress of the Spanish society medicine of family and community being held these days in Bilbao.

The 64 per cent of the population do not know the possibility of making a living will. And is that, Although the 84,5 per cent considered it useful and only to the 10 per cent think and speak of death bothers you, only a 6 per cent receive this information by medical personnel, a 22,3 per cent through the media and a 7,5 per cent by friends and family.

These data correspond to a study carried out in Catalonia, you have participated 264 people with an average age of 53 years and that have passed through the Centre of health since November of the 2011 until January of the 2012. In addition, they were presented at the thirty-second Congress of the Spanish society medicine of family and community (semFYC), being held these days in Bilbao.

As discussed by the authors of this experience, Irene Alcalá and Olga Bigas, the living will is still unknown by the majority of the population, Despite being a law based on the principle of autonomy. In his view, There is a “lack of information” adequately addressed to citizens.

In this sense, the President of the Organizing Committee of the Congress, Susana Martín, Remember that although the great legislative development occurs from the year 2000 the Basic Law of autonomy of the patient and the rights and obligations of clinical documentation and information, currently “they are few” studies on knowledge and attitudes of health workers about this.

“The dissemination of this information in the media play a fundamental role, as seen in this work. In general, physicians have a positive attitude towards the use and usefulness of this document and the posture of the patient is also favorable. However, This positive feeling contrasts with data that less than a 25 percent of adults completed the document. We can say that there is a predisposition to complete your advance, but not in the near future”, emphasizes Martin.

Also, the study reflects that they few health workers who start conversations with citizens on the advance planning for end of life care. In this sense, said Martin, physicians know “little” the standards, the content and the registration of this document. For this reason, He advocates seek alternatives to primary care consultations so that patients can report, through the nursing staff, social or auxiliary workers.

Experts are aware that the living will is only effective when there is a close relationship between the doctor and the patient. In this sense, the President of the Organizing Committee recognizes that most of the people it costs them talk about death, especially when it is your own, but regrets the lack of time that there are consultations hinders also arises the issue because “There is the fear of disturbing the patient”.

In this sense, the study reflects that most of the people considered that they should receive this information after an interview in which is explained –with the help of a triptych– the fundamentals and the tools to access the living will.

In addition, in the second part of the work on health workforce, highlights that the 34 per cent has been consulted once on this aspect and that is difficult to find own ignorance and lack of time. “Find it us interesting that although only the 10 percent of the surveyed patients discomfort it refers to talk about, the 46 per cent of health personnel it believed that for them it is. I.e., the patient does not ask for not knowing of its existence, and the workforce does not it ignorance and false beliefs about patients”, comment the authors.

The truth is that, as it gets evident this experience, There is an ignorance widespread on this issue as a 75,5 percent of patients ignore if you have legal validity; a 70,2 per cent do not know some of the aspects that aspects includes and more than the 80 percent unknown no are necessary witnesses, notary and legal representative.

In addition, a 83.4 per cent considered that all persons should receive information. “Currently we continue feeling more comfortable communicating such decisions verbally to the family, instead of writing. There is still a certain preference in the decisions in the hands of family and medical leave”, argues Martin.

Finally, the study reflects that knowledge and predisposition to consider the realization of the living will or recommend it is higher in people with secondary or higher education. “Our opinion on these differences is that it could be due to that persons with studies, in general, they have more tools when looking for information or keep up to date”, point out the authors.

By latest, These researchers recognize that he has surprised them the fact that age does not affect too as well as having suffered a serious illness or that of a family member, that could show greater sensitivity or knowledge on these topics. However, They recognize that the latter has failed to demonstrate it at work.

Medicosypacientes.com [en línea] Bilbao (ESP): medicosypacientes.com, 21 de junio de 2012 [REF. 14 in June of 2012] Available on Internet: http://www.medicosypacientes.com/sociedades/2012/06/12_06_14_semfyc



A retina from stem cells opens the doors of transplantation

18 06 2012

The team of the Kobe University, Japan, directed by Yoshiri Sasai, He has presented the generation ' in vitro'"optical glasses - embryonic structures from which arise the retinas- embryonic stem cells from human.

 

The success of the Group's Yoshiri Sasai, is the nearly perfect reproduction of the optic Cup. Thanks to a careful cropping system, embryonic stem cells gave rise spontaneously to an invaginated structure composed of two layers: an internal, that gives rise to the neural retina, and external, It forms the retinal pigment epithelium.

The process was similar to that which they had seen before with mouse stem cells but the result was slightly different. "They have shown that" There are variations between species in development, 'something important', drew Bovolenta. "The mouse cells generated a little smaller than the human retina", "that they originated a larger structure and with a similar proportion of cells that there are in the human eye".

An option for various diseases

"So far", "not had played so well the tissues of the eye retina", says Nuria Montserrat, researcher of the Center of regenerative medicine in Barcelona (CMRB). "They have achieved a spatial arrangement", with two layers, equal to reality. It's almost like an eye in a culture dish. This study opens the door to transplantation. But perhaps not to the classical idea of transplant, "where a damaged organ is replaced by a new one".

The first applications could be near. "In particular", for the retinitis pigmentosa, "where the photoreceptors of gradually degenerate", explains Sasai This medium. It could also be used, "in combination with" iPS cells, "to create models of disease in which study the pathogenesis and explore new treatments", Adds the Japanese researcher.

In Spain, There are several groups that are dedicated to research in this field. At the CMRB, they have "begun to make crops with stem cells and iPS" but they are still in preliminary stages, explains Nuria Montserrat

In the University Institute of applied ophthalmology (IOBA) the University of Valladolid There is a group dedicated to the retina where are also "trying to create structures in 3D tissue using stem cells", Adds Girish Kumar, who works there. They work with stem cells from fat, differentiating cells of the retina. Also looking for a treatment for the Industry associate of Macular degeneration and they have some animal studies that use stem cells to protect the retinal pigment epithelium. In all these fields, emphasizes Kumar, "this work will help us much".

Opticayvision.es [en línea]  (ESP): opticayvision.es, 18 de junio de 2012 [REF. 13 in June of 2012] Available on Internet: http://www.opticayvision.es/una-retina-de-celulas-madre-abre-las-puertas-del-trasplante



The epigenome of the newborn babies and the centenarians is different

14 06 2012

An international survey coordinated by Manel Esteller checks how epigenetic marks are degrading over time

Given that injuries epigenetic are reversible, could be to develop drugs that increase life time

What happens in our cells after one hundred years of life?? Do differ at the molecular level a newly born and a Centennial?? Is it changes gradual or sudden?? Is it possible to reverse the aging process?? What are the molecular keys to longevity?? These central issues in biology, Physiology and human medicine have been focus of study by researchers for decades.

Today, the international magazine Proceedings of the National Academy of Sciences (PNAS) It publishes a research of international collaboration directed by Manel Esteller, Director of the program in Epigenetics and biology of the Cancer of the Institute of biomedical research of Bellvitge (IDIBELL), Professor of genetics of the University of Barcelona and ICREA researcher, It provides an essential in this field track: the epigenome of the newborn babies and the centenarians is different.

While the genome of all the cells in the human body, irrespective of its appearance and function, is identical, the chemical signals that regulate, known as epigenetic marks, they are specific to each body and each human tissue. I.e., that all our components have the same alphabet (Genome), but the spelling (epigenome) It is different in every part of our Anatomy. The surprising outcome of the work of the Group of Dr. Esteller is that even for a same tissue or organ, the epigenome varies depending on the age of the person.

Representación gráfica de los epigenomas identificados, cuyos círculos interno, medio y externo corresponden respectivamente al individuo de 103 años, al de edad intermedia y al recién nacido.

Graphical representation of the identified epigenomes, whose inner circles, media and external correspond respectively to the individual's 103 years, the middle aged and the newborn.

In the study published in PNAS have been completely sequenced the epigenomes of white blood cells from a newborn, an individual of middle age and a person of 103 years. The results show that the Centennial presents a distorted epigenome that has lost many switches (methyl chemical group), charge off inappropriate gene expression and, on the other hand, the switch of some protective genes is turned off.

"Extending the results to a large group of infants", "individuals located in medium and nonagenarios point or centenarians give us account that every day that passes the epigenome is a progressive process that will twist", says researcher. However, Dr. Esteller stresses that "injury epigenetic", Unlike the genetic, they are reversible and, Therefore, "the modification of patterns of methylation of DNA by dietary changes or the use of drugs could induce an increase in the useful life".

Who we are

Bellvitge Biomedical Research Institute (IDIBELL) It is a research centre created year 2004. Is held by the Hospital Universitario de Bellvitge the Catalan Institute of health, the Catalan Oncology Institute, and the University of Barcelona. Is located in the Biopol 'H L' Hospitalet de Llobregat, and is a member of the Campus of international excellence of the University of Barcelona HUBc.

The article reference:

Heyn H, Li n, Ferreira HJ, Moran S, Pisano DG, A. Gómez, 10 J, Sanchez-Mut JV, Setién F, Carmona FJ, Pucaf AA Sayols S, Pujana MA, Serra-Musach J, Churches-silver I, Formiga F, Fernandez AF, Fraga MF, Heath S, Valencia to, Gut IG, Wang J, Esteller M. The Distinct DNA Methylomes of Newborns and Centenarians. Proc Natl Acad Sci USA, DOI10.1073, 2012.

Idibell.cat [en línea] Barcelona (ESP): idibell.cat, 14 de junio de 2012 [REF. 11 in June of 2012] Available on Internet: http://www.idibell.cat/modul/noticias/es/378/el-epigenoma-de-los-recien-nacidos-y-de-los-centenarios-es-distinto



Light, first private Center Spanish to endow the first Simulator capable of anticipating the effect of intraoperative radiotherapy.

11 06 2012

The The light clinic Madrid has become the first private hospital in Spain which has the new Planner Radiance ™ for intraoperative radiotherapy. It is a virtual Simulator that is unique in the world which allows to anticipate the effects of radiotherapy in tissues, planning the area precisely to radiate and therefore avoiding damage to surrounding healthy tissue.

In this way, within the framework of the intraoperative treatment of tumors, the specialist may have the most complete analysis of the patient for the decision-making process prior to surgical intervention, giving rise to the identification of the optimal treatment for each case.

Dr. Rosa Meiriño, Radiation Oncology clinic light unit, It says that "so far not had designed planners for the management of intraoperative radiotherapy".

The specialist explains that radiance ™ "enables the design of virtual tumor resection and bedding postreseccion and its adjacent structures; virtual manipulation of the cones of radiotherapy treatment and optimisation of doses in the bed of tumor resection". In this way is achieved "a management more accurate and precise irradiation, the intensification of dose in the tumor bed and minimizing dose to surrounding organs at risk".

Like this, the Planner, It represents the latest technology in the intraoperative treatment of tumors, It allows you to project distribution and radiation dose, among other critical parameters in these interventions.

Radiance ™ has been developed by the Spanish group GMV in collaboration with a research group that has led the Hospital General Universitario Gregorio Marañón and a set of Spanish universities and prestigious hospitals.

From 2001, year of the start of the activity in radiation oncology in La Luz, the clinic has with intraoperative radiotherapy in your unit, what already by itself guarantees your experience in this technique. The possibility of having this planner located at the center between the leading institutions around the world that are dedicated to this subspecialty and as first private clinic in Spain which has acquired this Simulator.

Radiotherapy is a type of cancer treatment that uses ionizing radiation to destroy, inactivated and control the tumor cells. Radiation therapy is, along with surgery and chemotherapy, one of the three pillars of the treatment of cancer, and it is estimated that more than the 50% patients with cancer they require treatment with radiotherapy to the tumour control, or as palliative therapy at some point in its evolution.

For its part, intraoperative radiation therapy is a technique that allows to direct a single dose of high intensity and dosimetry quality to the tumor bed during surgery, immediately after removal of the tumor or tumor not removed (residue), protecting radiation organs or tissues that are around, and they are not affected by the tumor.

This technique reduces the risk of recurrence of multiple types of tumors, as for example cancer of rectum, sarcomas or breast cancer, as well as the rescue with curative possibilities of cancer recidivado locally. It has also an important palliative value in other hardly curable types of cancer, as the pancreas.

It is interesting to note, also, that intraoperative radiotherapy can save time and frequency of visits hospital as such in early breast cancer, that can replace partial, and in some cases completely, external radiotherapy, reducing up to in 6 weeks overall treatment time. You can also even to become exclusive cancer treatment in specific cases. Furthermore this type of radiation therapy can minimize side effects on normal tissues (chronic sequelae), and it allows an optimization of the resources of the health system.

- This virtual tool, developed by Spanish technology group GMV, It allows to optimize the radiation and prevents damage to the healthy tissue

- Radiance ™ has the authorization of the American FDA and CE mark for medical device certification

About clinic light

The La Luz clinic is one of the most modern European complex clinical and Madrid's largest private healthcare centre. Since its inception, in 1978, the philosophy of the Clinica La Luz has been the patient consider the central axis of innovation-based healthcare and clinical excellence. Light, also, It is one of the best centres in the fields of healthcare, private community of Madrid and surrounding provinces.

Clinical Excellence de La Luz manifests itself in the ability to apply techniques and protocols of action advanced thanks to the presence of a team of specialists in prestige and first level, able to cover all areas of medicine, as well as in the availability and use of highly specialized resources and latest generation in the areas of consultation, diagnosis, surgery and post-operation. Today, the light clinic has a team of almost 80 specialists distributed in thirty departments and units.

GMV

GMV is a Spanish technology group founded in 1984, private equity and international presence. Operates in the following sectors: Aerospace, Defence and security, Transport, Health, Telecommunications and information technologies for public sector and large companies. He earned income in 2011 of more than 100 million euros, with a staff of more of 1.000 Professional. The company's growth strategy is based on continuous innovation, dedicating a 10% of its turnover to r & d. GMV has reached the level 5 CMMI, the top model of the world in terms of improving the ability of the processes of an organization and has numerous international patents.

Currently GMV is the first independent provider in the world of control systems on Earth for operators of commercial telecommunications satellites; the third European company by volume of participation in Galileo; the leading supplier of command and control the Spanish army C3I systems; the first national provider telematics systems for public transport. In the sector ICT has carried out flagship projects in the development and implementation of portals and platforms of mail, It has become benchmark national as a supplier of advanced security services in IP networks and solutions, ICT for public administrations and the development of e-Administration and mobility applications.

Noticiasmedicas.es [en línea] Madrid (ESP): noticiasmedicas.es, 11 in June of 2012 [REF. June of 2012] Available on Internet: http://www.noticiasmedicas.es/medicina/noticias/15088/1/La-Luz-primer-centro-privado-espanol-en-dotarse-del-primer-simulador-capaz-de-anticipar-el-efecto-de-la-radioterapia-intraoperatoria-/Page1.html#



Publicada la mayor base de datos del genoma del cáncer humano

7 06 2012

Madrid. (EP).- To accelerate progress in the fight against the cancer and other diseases, the draft of the genome of the Cancer Pediatric of the University of Washington, of the Children's Hospital St. Jude, It has announced the launch of the largest in the history of complete data of the Genome of the human cancer, for your free access to the world's scientific community.

La mayor base de datos del genoma del cáncer humano, disponible stjude.org

The largest database of the human cancer genome, available stjude.org

The amount of information released doubles the volume of available data at present all the human genome altogether. This information is valuable, not only for cancer researchers, but also for scientists who study almost any disease. the publication of these data is announced in Nature Genetics.

The 520 announced the genome sequences belong to normal and tumor tissue samples of 260 Pediatric patients of cancer - the Pediatric Cancer genome project hopes to have sequenced more than 1.200 genomes by the end of year.

Each sample was sequenced under a quality control that guarantees the maximum precision. The researchers from St. Jude analyzed genomic sequences to determine the differences between normal cells and the cancer of each child, to determine the causes of more than half a dozen most deadly childhood cancers, an effort that has already produced a series of key discoveries.

“This study has generated more discoveries of what we thought possible”, says James Downing, scientist who leads the project at St. Jude. Downing explains that “We want to make this information available to the scientific community in general, For what, collectively, We can explore new treatment options for children. To share information, We hope that other researchers can use this rich resource for investigating many other kinds of diseases, in children and adults”.

The Pediatric Cancer genome project, that began in 2010, is the largest effort in the world, to date, to understand the genetic origins of children's cancers. The project, three-year-old, will have an estimated cost of 65 millions of dollars. St. Jude covers 55 million of expenses, including a commitment of 20 millions of Kay Jewelers, a partner of St. Jude.

This is the first big project of the sequencing of the human genome, financed with private funds, share your data as soon as they are available. To date, This type of open access has been, to a large extent, restricted to Government-funded studies.

Researchers around the world can access the data from the stream via the European website European Genome-Phenome Archive, offering large open data sets to scientists.

Although most of the cancer genome efforts focus only on some genes, that it constituted a small part of the genome, Pediatric cancer researchers of this project have taken a different approach, sequencing the genome complete - all of the DNA- in each patient's tumor.

According to Dr. Richard k.. Wilson, Director of the Genome Institute at the University of Washington, “We have identified unusual changes in the cancer cells of many patients, that it had not found with other methods, and we are pleased to share these data with the scientific community”.

The Pediatric Cancer genome project has already made important discoveries about the aggressive childhood cancer of the retina, of brain stem, and blood. The project researchers who work in the eye tumor, retinoblastoma have discovered evidence of a rapid development of tumor, which has allowed them to identify a new and promising anti-cancer agent.

On the other hand, researchers who study the lethal leukemia in early childhood, known as childhood acute lymphoblastic leukemia, they discovered unexpected genetic alterations that could change the diagnosis and treatment in patients with this disease.

With regard to the efforts to understand the genetic changes that underlie a brain tumor, called diffuse intrinsic glioma, researchers found that an alarming 78 percent of the tumors they produced changes in two genes, that it had not been linked to cancer earlier.

More recently, the researchers of the project identified a genetic mutation associated with a chronic form of neuroblastoma, a discovery that offers the first clue about the genetic basis of the relationship between the results of treatment and age at the time of diagnosis.

“These findings would not have been possible without the Pediatric Cancer genome project”, says Downing. The expert concluded that these results provide new strategies for finding and treatment of high-risk cancers.

The project has demonstrated, also, the marked differences between pediatric and adult cancers, underscoring the importance of therapies specific to childhood cancer.

Herenciageneticayenfermedad.blogspot.com.es [en línea] (ESP): herenciageneticayenfermedad.blogspot.com.es, 7 in June of 2012 [REF. 28 in May of 2012] Available on Internet: http://herenciageneticayenfermedad.blogspot.com.es/2012/05/publicada-la-mayor-base-de-datos-del.html?utm_source = feedburner&utm_medium = feed&utm_campaign = Feed:+blogspot/CyMlg (herenciageneticayenfermedad)



Dr Pike: Innovation and health.

4 06 2012

Dr. Josep Manel Picas Vidal

Director of systems and ICT in theHospital de la Santa Creu i Sant Pau

 

Currently, the innovation concept is, probably, one of the most cited probably due to many factors, Surely the need generated by the current economic situation obliges us to rethink many of the things we do, in the sense of obtaining greater efficiency and effectiveness in particular, in the results obtained in the health action.

It is perhaps best to start with a correct definition, in this case I will use the one made by Vincent K. Omachonu and Norman G. Einspruch of the University of Miami in Florida, US, in their Innovation work in Healthcare Delivery Systems: A Conceptual Framework, published in The Innovation Journal: The Public Sector Innovation Journal, Volume 15(1), 2010, Article 2. defines innovation, also citing other researchers, as "the introduction and application, in a role, a group or an organization, of ideas, processes, products or processes, New in the adoption unit, appointed to significantly benefit the individual, to the Group, or in a broader sense to the society. In the same work they focus the health innovation must bear in mind the quality, costs, the patient safety, efficiency and health outcomes. It should focus on the patient in how looks it, as listen you and as their needs are covered.

This patient care forms an essential part of the concept of innovation, you receive qualifications as similar and open innovation as Eric Von Hippel, Professor at the MIT Sloan School of Management, Boston, US, in its Democratizing Innovation publication, that under license Creative Commons is freely accessible on the Internet.

The concept of innovation is so potent that, even the dynamic state of Massachusetts in US, It does flag of the concept of Revolutionary Innovation as a "brand" of your node for the attraction of investments and projects.

Innovation in health as defined in IBM in his "Healthcare study 2015 and Care Delivery"can focus on services (p.e. e-visitas) business processes (p.e. decision-making support systems)models (p.e. new medical devices) products (p.e. dispositivos médicos) social innovation and policy (p.e. new payment systems) management and culture of innovation (p.e. Security, quality...)p.e

It is worth to visit the blog of the Harvard Business Review on the 10 Innovations that transform medicine:

http://blogs.hbr.org/cs/2010/03/health_care_of_the_future.html

and it is worth entering in many of the concepts that there is on the subject and the adaptations of innovations that come from the industrial sector and services to the health sector, as to reference in my previous blog.

A fascinating world is opening, the value of the performances will be located as the main objective to achieve.